The Life Sciences and M&A teams advised Harpoon Therapeutics (Nasdaq: HARP) in its definitive agreement under which Merck (NYSE: MRK), through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million. The Board of Directors of Harpoon has unanimously approved the transaction. Closing of the acquisition is subject to certain conditions, including approval of the merger by Harpoon’s stockholders, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and other customary conditions. The transaction is expected to close in the first half of 2024.
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers designed to harness the power of the body’s immune system to treat patients suffering from cancer and other diseases.
The Goodwin team was led by Stuart Cable, Lisa Haddad and Jean Lee and included Amanda Gill, Wei Xu, Stephanie Barbanell, Sean Philbin, Samantha Davis, Evan De Ycaza, Maggie Wong, Marianne Sarrazin, Alicia Tschirhart, Amanda Rae Schwarzenbart, Manjinder Kaur, Alex Apostolopoulos, Erika Pey, Arman Oruc, Simone Waterbury, Andrew Jensen, Jacob Osborn, Carrie Miller, Gozde Guckaya, Christopher Denn, Katerina Stavrianidis, Aiste Zalepuga, Jo-an Chen, Julie Tibbets, Nathan Brodeur, Jacqueline Klosek, Gabe Maldoff, Lore Leitner, Annabel Loose, Rob Hale, Janelle Dempsey, Alexandra Denniston, Andre Amorim, Regina Couto, Benjamin Kurrass, Andrew Sucoff, Gaurika Amini, Matthew Wetzel, Brian Mukherjee, Deborah Birnbach and Christina Ademola.
For more details on the agreement, please read the press release.